GlassScriptPhysician profile
Thomas A Warr
NPI 1356342208
$7,678.32
in general payments reported to CMS, 2019-2025
57 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,482 · 2020: $303 · 2021: $501 · 2022: $619 · 2023: $1,417 · 2024: $2,300 · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,738 · Education: $34.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,738.26 |
| Education | $34.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,002.93 | 2019-2025 | Opdivo, Opdualag, Sprycel |
| Janssen Biotech, INC. | $760.89 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $609.73 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $529.91 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $410.88 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $408.14 | 2019-2024 | |
| Amgen INC. | $342.26 | 2019-2025 | Nplate, Vectibix, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $263.67 | 2019-2023 | Imbruvica |
| Pfizer INC. | $262.61 | 2019-2025 | |
| Beigene USA, INC. | $243.62 | 2023-2024 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $201.12 | 2019-2025 | |
| Emd Serono, INC. | $197.58 | 2024 | |
| Blueprint Medicines Corporation | $183.67 | 2021-2024 | Ayvakit |
| Adaptive Biotechnologies Corporation | $178.15 | 2023-2025 | Clonoseq |
| Eisai INC. | $169.96 | 2019-2024 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $135.63 | 2025 | Brukinsa |
| Exelixis INC. | $125.00 | 2025 | Cabometyx |
| Astellas Pharma US INC | $119.40 | 2019-2024 | Xtandi, Xospata |
| Celgene Corporation | $113.65 | 2019-2021 | |
| Genentech USA, INC. | $104.59 | 2019-2024 | Lunsumio, Alecensa, Tecentriq |
| Abbvie INC. | $100.56 | 2021-2025 | |
| Incyte Corporation | $82.05 | 2019-2024 | Jakafi, Monjuvi |
| Acrotech Biopharma INC. | $74.72 | 2023-2024 | Beleodaq |
| Sumitomo Pharma America, INC. | $73.37 | 2024-2025 | Orgovyx |
| Gilead Sciences, INC. | $73.13 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.00 | 2019-2024 | Ninlaro, Fruzaqla |
| Glaxosmithkline, LLC. | $70.60 | 2021-2025 | Ojjaara |
| Stemline Therapeutics INC. | $67.41 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $50.46 | 2021-2024 | Libtayo |
| Agios Pharmaceuticals, INC. | $47.32 | 2019-2024 | Pyrukynd |
| Daiichi Sankyo INC. | $44.92 | 2019-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $41.57 | 2019-2023 | |
| Seagen INC. | $38.95 | 2023 | Adcetris, Padcev |
| Medtronic, INC. | $33.98 | 2024 | Illumisite |
| Lilly USA, LLC | $33.67 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Alexion Pharmaceuticals, INC. | $33.45 | 2021-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $32.31 | 2019-2024 | Xarelto |
| Myovant Sciences INC. | $31.47 | 2021-2022 | |
| Coherus Oncology, INC. | $30.66 | 2023 | |
| Aurobindo Pharma USA, INC. | $27.60 | 2019-2020 | |
| Pharming Healthcare, INC. | $23.82 | 2023 | Ruconest |
| Foundation Medicine, INC. | $18.94 | 2020 | |
| Servier Pharmaceuticals LLC | $18.47 | 2024 | |
| Sobi, INC | $18.46 | 2023 | |
| Pharmaessentia USA Corporation | $17.67 | 2023 | Besremi |
| Exact Sciences Corporation | $17.64 | 2025 | The Cologuard Plus Collection Kit |
| Kite Pharma, INC. | $16.10 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $15.83 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.99 | 2024 | Oxlumo |
| Clovis Oncology, INC. | $13.76 | 2022 | |
| Karyopharm Therapeutics INC. | $13.66 | 2024 | Xpovio |
| Spectrum Pharmaceuticals INC. | $13.64 | 2024 | Rolvedon |
| Mirati Therapeutics, INC. | $13.53 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $13.36 | 2023 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.09 | 2024 | Gilotrif |
| Puma Biotechnology, INC. | $12.77 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Warr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.